This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713618290

Synthesis of Some Novel Sulfonamide Derivatives

M. M. Alya

^a Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt

To cite this Article Aly, M. M.(2007) 'Synthesis of Some Novel Sulfonamide Derivatives', Phosphorus, Sulfur, and Silicon and the Related Elements, 182:7,1497-1506

To link to this Article: DOI: 10.1080/10426500701242954 URL: http://dx.doi.org/10.1080/10426500701242954

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Phosphorus, Sulfur, and Silicon, 182:1497-1506, 2007

Copyright © Taylor & Francis Group, LLC ISSN: 1042-6507 print / 1563-5325 online

DOI: 10.1080/10426500701242954



Synthesis of Some Novel Sulfonamide Derivatives

M. M. Aly

Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt

Sulfapyridine (1) was selected as the starting material for the synthesis of some novel thiazolidine, thiosemicarbazide, and quinazoline derivatives. The structures of synthesized compounds were elucidated by elemental analyses and spectral data.

Keywords Quinazoline and sulfonamide derivatives; thiazolidine

INTRODUCTION

Substituted thiazolidines have been demonstrated to possess antibacterial,¹ antifungal,² anticonvulsant,³ anticancer,⁴ and antituberculosis⁵ activities. Also, thiazolidines have been reported as novel inhibitors of the bacterial enzyme Mur B, which was the precursor acting during the biosynthesis of peptidoglycan.⁶ Furthermore, antibacterial,⁷ antifungal,⁸ insulin releasing,⁹ carbonic anhydrase inhibitory,¹⁰ antiinflammatory,¹¹ and antitumor¹² properties of sulfamoyl moiety were described. As a continuation of our research program^{13–15} on the synthesis of heterocyclic compounds, in this article we report the synthesis of some novel thiazolidine and quinazoline derivatives containing sulfamoyl moiety from the readily available sulfapyridine (1).

RESULTS AND DISCUSSION

The non-isolable intermediate **2** was prepared by treatment of sulfapyridine (**1**) with carbon disulfide in dimethylformamide in the presence of potassium hydroxide at room temperature (Scheme 1). The non-isolable intermediate **2** was selected as starting material

Received September 11, 2006; accepted December 11, 2006.

Address correspondence to M. M. Aly, Chemistry Department, Faculty of Science, Al-Azhar University, P.O. Box 11884, Nasr City, Cairo, Egypt. E-mail: m.m.aly@hotmail.com

1498 M. M. Aly

SCHEME 1

for the synthesis of some novel thiazolidine and quinazoline derivatives. Thus, the reaction of the non-isolable intermediate **2** with some halo compounds was investigated. The cycloconden-sation of the non-isolable intermediate **2** with ethyl chloroacetate at room temperature

afforded 4-thiazolidinone derivative 3 (Scheme 1). The structure of 4thiazolidinone 3 was confirmed by elemental and spectral data. Its infrared spectrum showed characteristic absorption bands for NH, CHarom., C=O, C=N, and SO₂ functional groups. Also, its ¹HNMR (DMSO d_6) displayed a signal at $\delta = 4.20$ ppm assigned to CH₂ in addition to NH and aromatic protons. The formation of 3 is assumed to proceed via the initial alkylation by loss of sodium chloride followed by intramolecular cyclization through ethanol elimination. Treatment of the nonisolated intermediate 2 with α -bromobutyrate furnished thiazolidine derivatives 5 and structure 6 was ruled out on the basis of analytical and spectral data. The infrared spectrum of 5 exhibited absorption band at 3210 cm⁻¹ due to NH group and 1634 cm⁻¹ due to the C=N group. The ¹HNMR of (5; DMSO-d₆) revealed two ethyl groups in addition to NH and aromatic protons. The formation of 5 is assumed to proceed via the initial formation of intermediate 4 followed by elimination of water (Scheme 1). The non-isolable intermediate 2 was reacted with phenacyl bromide to yield the thiazolidine derivative 7 on the basis of analytical and spectral data. Its infrared spectrum showed absorption band at 3200 cm⁻¹ due to NH and no absorption band between 1600-1680 cm⁻¹ due to the absence of C=O group. The ¹HNMR spectrum of (7; DMSO-d₆) displayed the absence of methylene moiety, in addition to the presence of thiazolidine-H, NH, and aromatic protons. The reaction involves an initial alkylation by loss of sodium chloride followed by dehydration. Cyclization of the non-isolable intermediate 2 with the appropriate chloroacetonitrile produced 4-aminothiazolidine derivative 8. The structure of thiazolidine 8 was elucidated by elemental analysis and spectral data. Its infrared spectrum showed absorption bands at 3450, 3410 cm⁻¹ due to NH₂ group, and no absorption band was observed in the spectrum characteristic for C≡N group. The formation of 8 is assumed to proceed via initial alkylation followed by nucleophilic addition of secondary amino group to the cyano group and tautomerization (Scheme 1).

Alkylation of the non-isolable intermediate **2** with dimethyl sulfate afforded [4-(pyridin-2-ylsulfamoyl)-phenyl]-dithiocarbamic acid methyl ester **(9)** (Scheme 2). The structure of **9** was established on the basis of its elemental analysis and spectral data. The ¹HNMR spectrum of **(9**; DMSO-d₆) revealed a singlet at $\delta = 2.94$ ppm assigned to SCH₃ in addition to NH and aromatic protons. Reaction of compound **9** with methyl anthranilate in ethanol in the presence of triethylamine under reflux gave quinazoline derivative **11**. The structure of **11** was confirmed on the basis of elemental analysis, spectral data and alternative synthesis. Its infrared spectrum showed absorption band at 3222 cm⁻¹ due to NH group in addition to the presence of C=O (quinazolinone) at 1662 cm⁻¹.

1500 M. M. Aly

(2)
$$(CH_3)_2SO_4$$
 $(CH_3)_2SO_4$ $(CH_3)_2SO_4$ $(CH_3)_2SO_4$ $(COOCH_3)$ $(COOCH_3)$

SCHEME 2

Also, its 1H NMR spectrum (DMSO-d₆) revealed the absence of SCH₃ in addition to the presence of NH and aromatic protons. The formation of **11** is assumed to proceed via the initial formation of the intermediate **10** by loss of methyl mercaptan followed by intramolecular cyclization through methanol elimination. Also, quinazoline derivative **11** was obtained via another synthetic route by cyclization of anthranilate with isothiocyanate derivative **12**¹⁶ in dioxane under reflux in the presence of triethylamine. The novel thiosemicarbazide derivative **13** was achieved by treatment of compound **9** with hydrazine hydrate in ethanol at room temperature. Mass spectrum of **13** revealed a molecular ion peak at m/z = 323 (4.5%), and the base peak was found in the spectrum at m/z = 55.

The reaction of sulfapyridine (1) with chloroacetyl chloride in acetone containing 10% caustic soda at room temperature afforded the starting material N^4 -chloroacetylsulfanilamide derivative 14^{17} (Scheme 2). Refluxing of compound 14 with potassium thiocyanate in dimethylformamide furnished the novel 4-thiazolidinone derivative 16 in high

yield. The structure of 16 was established on the basis of analytical and spectral data. Its infrared spectrum revealed the absence of thiocvanate functional group in addition to the presence of NH and C=O functional groups. Also, mass spectrum showed a molecular ion peak at m/z = 283 [M-64 (SO₂); 100%], which is the base peak in the spectrum. The formation of 16 is assumed to proceed via the formation of intermediate 15 followed by intramolecular cyclization of amino group to the thiocyanate group (Scheme 2). The reactivity of 4-thiazolidinone 16 towards some electrophilic reagents was studied. Condensation of compo-und 16 with benzylidene-malononitriles (1:1 molar ratio) in ethanol in the presence of piperidine under reflux yielded the novel 4-thiazolidinone derivatives 17a,b. The structures of compounds 17a,b were confirmed on the basis of their elemental analysis, spectral data and alternative synthesis. Infrared spectra of compounds 17a,b showed the absence of absorption band for the cyano group. Mass spectrum of compound 17a displayed a molecular ion peak at m/z 410 [M-59 (HSCN); 2.71%, and the base peak was observed in the spectrum at m/z 405. The formation of 17 is assumed to proceed via Michael addition of the active methylene functional group to the activated ethylenic bond followed by the elimination of malononitrile¹⁸ to yield 17. Also, 4-thiazolidinone derivatives 17a,b were achieved by treatment of thiazolidine 16 with aromatic aldehyde in refluxing ethanol in the presence of piperidine. In a similar manner, condensation of 16 with tetracyanoethylene under reflux in ethanol in the presence of triethylamine afforded the corresponding cyanomethylene derivative 19. The structure of 19 was established on the basis of analytical and spectral data. Its infrared spectra showed the presence of cyano and NH functional groups. The formation of 19 is assumed to proceed via the formation of intermediate 18 followed by elimination of malononitrile¹⁸ to give 19 (Scheme 3).

CONCLUSION

The non-isolable intermediate **2** was used as starting material for the synthesis of some novel thiazole derivatives **3,5,7**, and **8** through its reaction, with α -halo compounds. Dithiocarbamic acid **9** was converted into the quinazoline derivative **11** by treatment with methyl anthranilate. The reaction of 4-thiazolidinone **16** with some electrophilic reagents was investigated.

EXPERIMENTAL

All melting points are uncorrected. IR spectra (KBr) were measured on Shimadzu 440 spectrometer, ¹H-NMR spectra were determined in

SCHEME 3

DMSO-d $_6$ on a Varian Gemini 200 MHz spectrometer using TMS as internal standard. Chemical shifts are expressed as δ ppm units. Mass spectra were obtained on GCMS 1000 Ex mass spectrometer at 70 eV. Elemental analyses were carried out at the Microanalytical Center of Cairo University. The characteristics data for prepared compounds are given in Table 1.

Compd.	Yield	Solvent	M.p.	Mol. formula	Elemental analyses calcd./found %			
no.	(%)	cryst.	(°C)	(mol. wt.)	C%	Н%	N%	S%
3	78	Acetic acid	145–46	$C_{14}H_{11}N_3O_3S_3$	46.01	3.03	11.50	26.32
5	67	Dioxane	154-56	(365.45) $C_{18}H_{19}N_3O_3S_3$	46.00 51.28	3.00 4.54	11.40 9.97	26.20 22.82
7	65	Acetic acid	160–62	$\substack{(421.56)\\C_{20}H_{15}N_3O_2S_3}$	51.00 56.45	$4.50 \\ 3.55$	$9.90 \\ 9.87$	22.80 22.61
8	60	Ethanol	170-72	$\substack{(425.55)\\ C_{14}H_{12}N_4O_2S_3}$	56.30 46.14	$3.50 \\ 3.32$	$9.70 \\ 15.37$	22.50 26.39
9	64	Dioxane	140–41	$\substack{(364.47)\\C_{13}H_{13}N_3O_2S_3}$	$46.00 \\ 46.00$	$3.20 \\ 3.86$	15.30 12.38	26.30 28.34
11	55	DMF	285–87	(339.46) $C_{19}H_{14}N_4O_3S_2$	45.90 55.60	3.90 3.44	12.30 13.65	28.30 15.62
13	57	Dioxane	195–97	(410.47) $C_{12}H_{13}N_5O_2S_2$	55.50 44.57	3.40 4.05	13.50 21.66	15.50 19.83
16	63	Dioxane	240-42	(323.39) $C_{14}H_{12}N_4O_3S_2$	44.50 48.26	4.10 3.47	21.60 16.08	19.80 18.41
17a	70	Acetic Acid	290–92	(348.40) $C_{21}H_{15}ClN_4O_3S_2$	48.20 53.56	3.40 3.21	16.00 11.90	18.30 13.62
17b	72	Acetic Acid	>300	$\substack{(470.95)\\ C_{22}H_{18}N_4O_4S_2}$	53.50 56.64	3.10	11.80 12.01	13.50 13.75
19	52	Dioxane	150—51	$\substack{(466.53)\\ C_{17}H_{10}N_6O_3S_2\\ (410.43)}$	56.60 49.75 49.70	3.70 2.46 2.40	11.90 20.48 20.40	13.70 15.63 15.50

DMF = dimethylformamide.

Reaction of 1 with Ethyl Chloroacetate, α-Bromobutyrate, Phenacyl Bromide or Chloroacetonitrile Formation of Compounds 4-(4-Oxo-2-thioxo-thiazolidin-3-yl)-N-pyri-din-2-yl-benzenesulfonamide (3), 4-(4-Ethoxy-5-ethyl-2-thioxo-thiazol-3-yl)-N-pyridin-2-ylbenzenesulfonamide (5), 4-(4-Phenyl-2-thioxo-thia-zol-3-yl)-N-pyridin-2-yl-benzenesulfonamide (7) and 4-(4-Amino-2-thioxo-thiazol-3-yl)-N-pyridin-2-yl-benzenesulfonamide (8) (General Procedure)

To a suspension of finely powdered sodium hydroxide (0.04 g, 0.01 mol) in dry dimethylformamide (10 ml) at 0° C, the carbon disulfide (0.76 g, 0.01 mol) and sulfapyridine (1) (2.49 g, 0.01 mole) were added in portions. The reaction mixture was stirred at room temperature for 3 h and then treated with α -halo compound (0.01 mol) and left at room temperature for 24 h; then, it was poured into ice/water and acidified with 0.1 N HCl at pH 3–4. The resulting precipitate was filtered off,

1504 M. M. Aly

TABLE II Spectral Data of the Synthesized Compounds.

Compd. no.	$IR/\nu_{max}~(cm^{-1})$	$^{1}\mathrm{H}$ NMR (DMSO- d_{6}) (δ / ppm)
3	3210 (NH), 2932 (CH-aliph), 1634 (C=N), 1366, 1140 (SO ₂)	4.20 (s, 2H, CH ₂), 6.85–8.02 (m, 8H, Ar–H), and 10.3 (s, 1H, NH)
5	3210 (NH), 2932 (CH-aliph), 1634 (C=N), 1366, 1140 (SO ₂)	1.02 (t, 3H, CH ₃), 1.99 (t, 3H, CH ₃), 3.41 (q, 2H, CH ₂), 4.5 (q, 2H, CH ₂), 6.56–7.99 (m, 8H, Ar–H), and 10.42 (s, 1H, NH)
7	3200 (NH), 1558 (C=N), 1362, $1136~(\mathrm{SO}_2)$	4.59 (s, 1H, NH), 6.3 (s, 1H, thiazolidine-H) and 6.63–7.78 (m, 13H, Ar–H)
8	$\begin{array}{c} 3450,3410\;(\mathrm{NH_2}),2926\\ (\mathrm{CH\text{-}aliph.}),1634\;(\mathrm{C}\!\!=\!\!\mathrm{N}),1390,\\ 1138\;(\mathrm{SO_2}) \end{array}$	_
9	3264 (NH), 3050 (CH-arom.), 2922 (CH-aliph.)	2.94 (s, 3H, CH ₃), 6.54-8.11 (m, 8H, Ar—H), 9.32, 11.9 (2s, 2H, 2NH)
11	3222 (NH), 3036 (CH-arom.), 1662 (C=O; quinazolinone), 1610 (C=N), 1328, 1140 (SO ₂)	$6.89-7.99 \; (m,\; 14H,\; Ar\!-\!\!H + NH), \\ 13.14 \; (s,\; 1H,\; NH)$
13	3458, 3330 (NH/NH ₂), 3060 (CH-arom.), 1338,1150 (SO ₂)	_
16	3252, 3190 (2NH), $\overline{1686}$ (C=O), $\overline{1628}$ (C=N), $\overline{1388}$, $\overline{1136}$ (SO ₂)	$\begin{array}{c} 4.01\ (s,2H,CH_2),6.84–8.01\ (m,\\ 8H,Ar-\!$
17a	3280, 3200 (2NH), 1680 (C=O), 1608 (C=N), 1364, 1140 (SO ₂)	
17b	$3320 (\mathrm{NH}), 2930 (\mathrm{CH}\text{-aliph.}), 1602 \\ (\mathrm{C}\!\!=\!\!N), 1382, 1138 (\mathrm{SO}_2)$	$3.6 (s, 3H, OCH_3), 6.67-7.78 (m, 15H, Ar-H + benzylidene-H + 2NH)$
19	$\begin{array}{c} 3250 \ (\mathrm{NH}), 2110 \ (\mathrm{C}\!\!=\!\!\mathrm{N}), 1682 \\ (\mathrm{C}\!\!=\!\!\mathrm{O}), 1624 \ (\mathrm{C}\!\!=\!\!\mathrm{N}), 1384, 1128 \\ (\mathrm{SO}_2) \end{array}$	$4.3 \ (\mathrm{s}, 1\mathrm{H}, \mathrm{NH}), 6.87.9 \ (\mathrm{m}, 9\mathrm{H}, \\ \mathrm{Ar-\!H} + \mathrm{NH})$

dried, and recrystallized from the proper solvent to yield 3, 5, 7, and 8, respectively.

Synthesis of Compound [4-(Pyridin-2-ylsulfamoyl)-phenyl]-dithiocar-bamic Acid Methyl Ester (9)

The experimental procedure for **3** was carried out except for the use of dimethylsulfate instead of the halo compound.

Synthesis of Compound 4-(4-Oxo-2-thioxo-1,4-dihydro-2H-quinazolin-3-yl)-*N*-pyridin-2-yl-benzenesulfonamide (11)

Method A

A mixture of compound **9** (3.39 g, 0.01 mol), methyl anthranilate (1.51 g, 0.01 mol), and triethylamine (1.01 g, 0.01 mol) in ethanol (20

ml) was heated under reflux for 12 h. The solid product which produced on heating was collected and recrystallized from the proper solvent.

Method B

A mixture of compound **12** (2.91 g, 0.01 mol), methyl anthranilate (1.51 g, 0.01 mol), and triethylamine (1.01 g, 0.01 mol) in ethanol (20 ml) was heated under reflux for 1h. The solid product which produced on heating was collected and recrystallized to give **11**.

Synthesis of Thiosemicarbazide Derivative (13)

To a suspension of compound **9** (3.39 g, 0.01 mol) in ethanol (30 ml), the appropriate hydrazine hydrate (0.5 g, 0.01 mol) was added in portions with stirring. The reaction mixture was stirred at room temperature for 30 min; the solid that separated out was filtered off and recrystallized from the proper solvent to give **13**.

Synthesis of 4-(2-lmino-4-oxo-thiazolidin-3-yl)-N-pyridin-2-yl-benzene-sulfonamide (16)

A suspension of compound 14 (3.25 g, 0.01 mol) and potassium thiocyanate (0.96 g, 0.01 mol) in dimethylformamide (10 ml) is heated under reflux for 1 h. After cooling the reaction mixture is poured into water (100 ml), the precipitate is separated by filtration and washed with water to give 16.

Synthesis of 4-[5-(2-Chlorobenzylidene)-2-imino-4-oxothiazolidin-3-yl]-*N*-pyridin-2-yl-benzenesulfonamide (17a) and 4-[5-(4-Methoxy-benzylidene)-2-imino-4-oxo-thiazolidin-3-yl]-*N*-pyridin-2-yl-benzene-sulfonamide (17b)

Method A

A mixture of compound **16** (3.48~g,~0.01~mol), benzylidenemalononitrile (0.01), and piperidine (0.85~g,~0.01~mol) in ethanol (20~ml) was heated under reflux for 3h. The solid product which produced on heating was collected and recrystallized from the proper solvent to give **17**.

Method B

A mixture of compound $16 (3.48 \, \text{g}, 0.01 \, \text{mol})$, aromatic aldehyde $(0.01 \, \text{mol})$, and piperidine $(0.85 \, \text{g}, 0.01 \, \text{mol})$ in ethanol $(20 \, \text{ml})$ was heated under reflux for 1 h. The solid product was collected and recrystallized to give 17.

Synthesis of 4-(5-Dicyanomethylene-2-imino-4-oxothiazolidin-3-yl)-N-pyridin-2-yl-benzenesulfonamide (19)

A mixture of compound **16** (3.48 g, 0.01 mol), tetracyanoethylene (1.28 g, 0.01 mol), and triethylamine (1.01 g, 0.01 mol) in ethanol (20 ml) was heated under reflux for 0.5h. The solid product which produced on heating was collected and recrystallized to give **19**.

REFERENCES

- [1] S. G. KücüKgüzel, E. E. Oruc, S. Rollas, F. Sahin, and Ozbek, Eur. J. Med. Chem., 37, 197 (2002).
- [2] G. Capan, N. Ulusoy, N. Ergenc, and M. Kiraz, Monatshefte für Chemie, 130, 1399 (1999).
- [3] N. Ergenc and G. Capan, IL Farmaco, 49, 133 (1994).
- [4] J. J. Bhatt, B. R. Shah, H. P. Shah, P. B. Trivedi, N. K. Undavia, and N. C. Desai, Indian J. Chem., 33B, 189 (1994).
- [5] L. Bukowski, M. Janowiec, Z. Zwolska, and Z. Andrejczyk, *Pharmazie*, 53, 373 (1998).
- [6] C. J. Andres, J. J. Bronson, S. V. Andrea, M. S. Deshpande, P. J. Falk, K. A. Grant, W. E. Harte, H. T. Ho, P. F. Misco, J. G. Robertson, D. Stock, Y. Sun, and A. W. Walsh, *Bioorg. Med. Chem. Lett.*, 10, 715 (2000).
- [7] M. S. A. El-Gaby, A. A. Atalla, A. M. Gaber, and K. A. Abd Al-Wahab, IL Farmaco, 55, 596 (2000).
- [8] M. S. A. El-Gaby, A. M. Gaber, A. A. Atalla, and K. A. Abd Al-Wahab, IL Farmaco, 57, 613 (2002).
- [9] T. H. Marene, Ann. Rev. Pharmacol. Toxicol., 16, 309 (1976).
- [10] C. T. Supuran, A. Scozzafava, B. C. Jurca, and M. A. Iies, Eur. J. Med. Chem., 33, 83 (1998).
- [11] J. J. Li, D. Anderson, E. G. Burton, J. N. Cogburn, J. T. Collins, D. J. Garland, S. A. H. Huang, P. C. Isakson, C. M. Koboldt, E. W. Logusch, M. B. Morton, W. Perkins, E. J. Reinhard, K. Seibert, A. W. Veenhuizen, Y. Zhang, and D. B. Reitz, *J. Med. Chem.*, 38, 4570 (1995).
- [12] S. M. Sondhi, M. Johar, N. Singhal, S. G. Dastidar, R. ShuKla, and R. Raghubir, Monatshefte für Chemie, 131, 511 (2000).
- [13] M. M. Ali, M. M. F. Ismail, M. S. A. El-Gaby, M. A. Zahran, and Y. A. Ammar, Molecules, 5, 864 (2000).
- [14] Y. A. Ammar, A. M.Sh. El-Sharief, M. M. Ali, Y. A. Mohamed, M. S. A. El-Gaby, A. S. Aly, and Sh.I. Mohamed, *Phosphorus, Sulfur and Silicon*, **166**, 173 (2000).
- [15] A. M. Sh. El-Sharief, Y. A. Ammar, Y. A. Mohamed, M. M. Ali, and M. S. A. El-Gaby, Phosphorus, Sulfur and Silicon, 173, 39 (2001).
- [16] M. S. A. El-Gaby, Phosphorus, Sulfur and Silicon, 156, 157 (2000).
- [17] U. P. Basu, J. Ind. Chem. Soc., 466 (1947).
- [18] H. Junek, G. Zuschnig, R. Thierrichter, G. Gfrerer, and H. Sterk, Monatshefte für Chemie, 113, 1045 (1982).